Name: Matične stanice
Brand: Labbieux

Matične stanice

Dostupno kvalificiranim profesionalnim partnerima.

Matične stanice prirodni su sustav obnove tijela i ključne su za cijeljenje i regeneraciju. U Labbieuxu su naše napredne UC-MSC terapije (mezenhimalne matične stanice iz pupkovine) precizno razvijene za poticanje oporavka i regeneracije na određenim mjestima. Budući da matične stanice aktivno obnavljaju oštećeno tkivo i ponovno uravnotežuju imunološki sustav, djeluju na kronična stanja, ozljede i posljedice starenja na staničnoj razini: ondje gdje konvencionalne terapije ne mogu doprijeti.

Otkrijte naše programe

Infuzijska vrećica

Istraživanje pokazuje

Diferencijacija u koštane, hrskavične i masne stanice in vitro
Parakrina signalizacija pri obnovi i regeneraciji tkiva
Imunomodulacijska aktivnost unutar upalnih putova
Proangiogena signalizacija i remodeliranje izvanstaničnog matriksa

Pogledajte Matične stanice u našoj istraživačkoj knjižnici

Biblioteka na engleskom jeziku

Postanite B2B partner Osobno istraživanje

Djelovanje

Kako djeluju matične stanice

Istraživanje UC-MSC-a usmjereno je i na aktivnost samih stanica i na njihovu parakrinu signalizaciju. Oslobađaju citokine, čimbenike rasta i izvanstanične vezikule koji mogu utjecati na susjedne stanice. Laboratorijska i klinička istraživanja također proučavaju njihov potencijal diferencijacije i interakciju s upalnim i imunološkim putovima.

Istraživanje

Istraživanje o Matične stanice

Odabir relevantnih publikacija i registriranih studija, s izravnim poveznicama na originalne izvore.

Najvažnije publikacije

5 publikacija iz Research Library.

Vrsta dokaza

Publikacija i ključni nalaz

Izvor

Vrsta dokaza

Randomizirano ispitivanje na ljudima

Direct UC-MSC phase I and randomized phase II cartilage evidence

Publikacija i ključni nalaz

Cytopeutics umbilical cord-derived mesenchymal stem cells are associated with earlier clinical improvement compared to bone marrow aspirate concentrate with scaffold in knee cartilage injury: A Phase 1 feasibility and Phase 2 randomized controlled trial.

In a phase I feasibility study and 28-person phase II randomized trial, UC-MSCs with hyaluronic acid were associated with earlier pain relief and functional improvement than bone-marrow aspirate concentrate with scaffold.

The Medical journal of Malaysia

Izvor

Pogledajte publikaciju na PubMedu

PMID 41914582 · 2026

Vrsta dokaza

Randomizirano ispitivanje na ljudima

Direct UC-MSC randomized knee-osteoarthritis evidence

Publikacija i ključni nalaz

Intra-articular injection of umbilical cord-derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double‑blinded and randomized controlled trial.

In a 55-participant double-blind randomized trial, UC-MSC injection produced significant six-month improvements in pain, function and synovitis among participants with knee osteoarthritis and synovitis; no serious treatment-related adverse events were reported.

BMC musculoskeletal disorders

Izvor

Pogledajte publikaciju na PubMedu

PMID 41466394 · 2025

Vrsta dokaza

Randomizirano ispitivanje na ljudima

Direct UC-MSC randomized aging-frailty evidence

Publikacija i ključni nalaz

Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study.

A randomized, double-blind, placebo-controlled frailty study reported six-month improvements in physical quality-of-life scores, timed up-and-go and grip strength, with no difference in adverse-event incidence between groups.

Stem cell research & therapy

Izvor

Pogledajte publikaciju na PubMedu

PMID 38679727 · 2024

Vrsta dokaza

Randomizirano ispitivanje na ljudima

Direct UC-MSC randomized phase II type-2-diabetes evidence

Publikacija i ključni nalaz

Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial.

In a 91-person double-blind phase II trial, 20% of the UC-MSC group versus 4.55% of the placebo group met the combined 48-week HbA1c and insulin-reduction endpoint; no major transplantation-related adverse events were reported.

Stem cell research & therapy

Izvor

Pogledajte publikaciju na PubMedu

PMID 35505375 · 2022

Vrsta dokaza

Randomizirano ispitivanje na ljudima

Direct UC-MSC randomized phase I/II heart-failure evidence

Publikacija i ključni nalaz

Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).

In a 30-person phase I/II randomized heart-failure trial, the UC-MSC group showed improvements in left-ventricular ejection fraction, functional class and quality of life, with no infusion-related adverse events reported.

Circulation research

Izvor

Pogledajte publikaciju na PubMedu

PMID 28974553 · 2017

Registrirane kliničke studije

5 odabranih studija iz Research Library, poredanih prema relevantnosti za ovaj proizvod.

Traže se sudioniciFaza 3

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

398 registriranih sudionikaShanghai IxCell Biotechnology Co., LTD

Pogledajte studiju na ClinicalTrials.gov

NCT06716281

Traže se sudioniciFaza 2

Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells As an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients

41 registriranih sudionikaEver Supreme Bio Technology Co., Ltd.

Pogledajte studiju na ClinicalTrials.gov

NCT06147986

Aktivno, bez novih sudionikaFaza 1 / faza 2

Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis

9 registriranih sudionikaBeijing Baylx Biotech Co., Ltd.

Pogledajte studiju na ClinicalTrials.gov

NCT04971980

Traže se sudioniciFaza 1 / faza 2

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis

41 registriranih sudionikaEver Supreme Bio Technology Co., Ltd.

Pogledajte studiju na ClinicalTrials.gov

NCT05532943

ZavršenoFaza 1 / faza 2

Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study）

40 registriranih sudionikaShanghai East Hospital

Pogledajte studiju na ClinicalTrials.gov

NCT04992832

Pogledajte Labbieux Research Library na engleskomBiblioteka na engleskom jezikuPogledajte sve istraživačke zapise za Matične stanice ili otkrijte istraživanja o svim našim proizvodima.Otvorite knjižnicu

Matične stanice

Podaci o proizvodu

Kako djeluju matične stanice

Što čine matične stanice

Istraživanje signala za obnovu tkiva

Istraživanje imunoloških putova

Razvoj u različite vrste stanica

Kontrolirana isporuka profesionalcima

Istraživanje o Matične stanice

Najvažnije publikacije

Cytopeutics umbilical cord-derived mesenchymal stem cells are associated with earlier clinical improvement compared to bone marrow aspirate concentrate with scaffold in knee cartilage injury: A Phase 1 feasibility and Phase 2 randomized controlled trial.

Intra-articular injection of umbilical cord-derived mesenchymal stem cells is safe and effective for moderate to severe knee osteoarthritis with synovitis: a double‑blinded and randomized controlled trial.

Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study.

Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial.

Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).

Registrirane kliničke studije

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells As an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients

Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis

Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study）

Profesionalni kriogeni format

Napomene o rukovanju

Certifikat o analizi (COA)

Stem cells